The Handoff Illusion: Why Clean Transitions in Clinical Development Are a Myth

Clinical development is organized around transitions. Strategy hands off to operations. Operations hands off to vendors. One phase completes and the next begins. The model feels efficient. It has the clarity of a relay race with defined lanes, clean exchanges, forward momentum. It is also largely fiction.

Clinical development does not progress through clean handoffs. It operates as an integrated system of persistent dependencies, where decisions made in one domain create constraints in another that outlast the transition. The baton does not transfer cleanly because the baton never fully passes. Nor should it.

The first two articles in this series examined why execution strategy must begin at the business decision and what qualified people must do to bridge scientific intent into operational reality before commitments harden. This article examines what happens next, when that early work, however deliberately executed, is treated as complete once the transition occurs. It is not. What keeps an integrated system aligned is not the quality of its handoffs. It is the quality of its facilitation, the sustained, active engagement of people who understand how the system's dependencies interact and who intervene before misalignment compounds. That facilitation is often invisible when it is working. When it stops, the consequences appear downstream, where the unmanaged dependency surfaces as a vendor scope gap labeled a performance problem, a timeline slip, or an inspection finding that traces back to a decision nobody owned.

The term 'integrated system' is easy to accept in principle and easy to ignore in practice. Clinical development feels like a sequence of phases because that is how it is planned, budgeted, and reported. Each function has its lane.

What the phase model obscures is that the dependencies between those lanes persist long after the formal transition between them. Strategy does not end when operations begins. The assumptions embedded in strategy, about feasibility, timelines, and vendor scope, continue to govern how execution behaves months and sometimes years later.

The same dynamic operates across functions within the sponsor organization. Regulatory, CMC, safety, and data decisions each create constraints that downstream functions must absorb. Those dependencies persist whether or not anyone has made them visible.

The same is true across the vendor network. CROs, central laboratories, and specialty vendors execute within defined scopes. What no vendor owns is the integration between them such as the data flows, system interfaces, escalation pathways, and cross-functional dependencies that span organizational boundaries. That integration is sponsor work. It cannot be contracted or transferred through a TORO. It exists only if it is actively maintained. Integration is most vulnerable at the seams. Facilitation is how it is actively maintained. Both are sponsor responsibilities. Neither transfers with a contract.

It is the qualified people bridging scientific intent, those who have developed the pattern recognition to see across complex systems simultaneously, interpret signals before they become issues, and recognize a dependency at risk before it surfaces in a report. This is not administrative coordination. It is the interpretive judgment that develops through direct operational experience, through programs that didn't go as planned, through the accumulated scar tissue of knowing what an email actually means before the second paragraph.

That capability doesn't show up on a dashboard. It shows up in what doesn't go wrong.

The most consequential expression of the handoff illusion is what happens when sponsors outsource clinical trial execution and treat the contract as the execution handoff rather than the foundation of an ongoing oversight obligation. While this article focuses on clinical execution and GCP obligations specifically, the sponsor oversight gap described here is not unique to clinical development. The same pattern appears across GMP-regulated functions.

Clinical execution is where the asset meets the real world. The capital that funded the science, the data that will support the submission, and the patients who enrolled in the trial all operate within that system simultaneously. Treating the contract as the execution handoff leaves the most consequential phase of asset development without the active stewardship it requires.

CROs execute within the scope sponsors define. They deliver against contracted deliverables, manage their own workflows, and report against agreed metrics. What no contract can require them to do is maintain the sponsor's strategic intent across the execution system. That obligation remains with the sponsor.

When sponsors operate as though oversight transferred with the contract, the gap opens quietly. Signals go uninterpreted. Dependencies go unmanaged. Decisions default to the CRO. By the time consequences surface, correction is expensive and options are limited. What is less visible is where the risk went in the meantime. Reduced oversight, compressed timelines, and tighter resourcing collectively shift how much risk the asset is carrying into execution, the most vulnerable phase of development. The asset absorbs it quietly until the cost becomes visible. ICH E6(R3) is explicit, sponsors may delegate tasks but not responsibility. That standard requires active presence, not distance.

The outsource and forget model is rarely a deliberate choice. It is a cost containment decision built on a flawed assumption that outsourcing execution transfers the risk along with the work. It does not. It transfers visibility of the risk to the vendor network while accountability remains with the sponsor. From the inside the model looks like efficiency. From an inspection, a submission delay, or a program that ran out of runway, it looks like something else entirely. It is, in the most literal sense, an oversight of their oversight.

The handoff illusion is not limited to the sponsor-CRO relationship. It operates with equal consequence inside sponsor organizations, across the cross-functional dependencies that shape execution.

Each function makes decisions within its domain. What is often unowned is the active integration of those decisions across functions and the continuous facilitation required to manage their downstream effects throughout the trial lifecycle. Integration as a sustained obligation, not a one-time delivery.

A recurring pattern illustrates this clearly. Investigational product (IP) expiry is a CMC-defined constraint. Stability data is generated, maintained, and extended within the CMC function, and when a trial is actively enrolling and dosing, stability extension is not a one-time deliverable. It is a continuous obligation. In practice, however, expiry management is often treated as a static handoff. CMC generates the initial stability data and considers the obligation met. Clinical teams are left tracking approaching expiry dates and requesting updated IP stability documentation on behalf of a trial that CMC is not actively watching. When the request comes late, or not at all, the issue surfaces in execution as an investigational product gap, even though the constraint originated in CMC, where the stability data, authority, and decision-making control to extend expiry reside.

The regulatory frameworks establish where expertise resides. Stability and expiry are defined within CMC under GMP. Use and control of IP in the field operate under GCP. Oversight of how those responsibilities connect sits with the sponsor, through integration and facilitation that is designed in, not added on.

What closes these gaps is deliberate design of cross-functional accountability, beginning with clarity about which function owns each constraint and sustained through active facilitation of its downstream implications. A constraint that requires another function to request its continuation is not being actively owned. Constraints must remain owned by the functions that define them, including actively managing their lifecycle and maintaining visibility into when they will become operationally limiting. Their implications must be visible across the system. When this is structured, functions operate with each other. The alternative, functions operating around each other, is where execution absorbs the difference.

Clarity about what active facilitation requires begins with clarity about what cannot be handed off. Certain responsibilities remain unequivocally sponsor-owned. Recognizing them explicitly is the first step toward designing an oversight model that actually fulfills them.

Regulatory reporting and safety obligations remain with the sponsor. A CRO may support pharmacovigilance processes. Accountability for safety decisions remains a standing sponsor responsibility throughout.

Moving from protocol intent into executable operational models is sponsor work. The protocol describes what the study is designed to learn. Converting that intent into an operational model that sites can follow, vendors can execute, and regulators can inspect requires sponsor judgment, sponsor decisions, and sponsor ownership. A CRO can co-develop the model. It cannot own the intent behind it.

Definition of risk tolerance is sponsor-owned. What constitutes critical versus acceptable risk in a given program is not a vendor determination. It reflects the sponsor's scientific objectives, regulatory strategy, and asset development priorities. When risk tolerance is undefined or defaulted to the CRO, execution proceeds without a compass.

Co-authorship and approval of study-specific execution plans establishes accountability for the life of the study. These plans are sponsor decisions about how the study will be managed, how oversight will be demonstrated, and how accountability will be distributed across clinical management, safety, data, monitoring, IP logistics, laboratories, sites, and vendor oversight. Once approved, they are no longer vendor paperwork. They are evidence of sponsor oversight.

Resolution of cross-functional conflicts across clinical execution, safety, data, regulatory, and operational domains remains sponsor-owned. This includes facilitation and issue resolution across vendors and between vendors and internal sponsor departments. No vendor resolves conflicts that span organizational boundaries. No vendor owns the integration between other vendors. That authority resides with the sponsor, or it resides nowhere.

Confirmation of inspection readiness before first subject enrollment is a sponsor obligation requiring the sponsor to attest with confidence that the oversight framework, the execution plans, the vendor relationships, and the site activation activities collectively meet the standard regulators will assess. That attestation cannot be delegated, cannot be created retrospectively, and can only be made by a sponsor who has been present, engaged, and informed throughout.

These responsibilities do not transfer with a contract. They do not migrate to a vendor through a TORO. They are fulfilled through sustained, informed engagement across the lifecycle, or they are not fulfilled at all. That gap has two origins. Sometimes it is an oversight design problem where accountability was never explicitly structured, and ownership was never deliberately assigned. More often it is an oversight capacity problem. The design may exist, but the team carrying it has been compressed to the point where fulfillment is structurally impossible. Both produce the same result. The handoff illusion fills the space that sponsor oversight was supposed to occupy, and the program absorbs the consequence in the form of a sponsor oversight inspection finding, a data integrity question, or an asset that reached the finish line carrying risks that active oversight would have caught and corrected.

Clinical development is not a relay race. The dependencies that shape execution persist across phases, across organizational boundaries, across the full lifecycle of a program, and they require continuous, active management to remain aligned.

The handoff illusion is a design blind spot. When sponsors treat the contract as the execution handoff, when functions assume downstream impact is someone else's tracking, when oversight capability is compressed to the point where sustained engagement is structurally impossible, the system does not announce the gap. It absorbs it quietly at a cost.

What replaces the handoff model is the deliberate, continuous engagement of qualified sponsor personnel who understand how the system's dependencies interact, who maintain visibility across functions and vendors simultaneously, and who intervene before misalignment compounds into something harder and more expensive to correct. It is not more process layers or reporting. It is active ownership and facilitation.

The moment a sponsor stops actively facilitating is often invisible. Weeks or months later the signal arrives. Vendor scope gaps labeled performance problems, timeline slips attributed to site behavior, and inspection findings that trace back to decisions nobody owned. By then the distance between what happened and what should have happened is difficult to close and expensive to explain.

Active facilitation is not an add-on to execution. It is the condition that makes execution controllable. It is either designed in from the beginning or recovered at significant cost later. The organizations that understand this don't wait for the gap to announce itself. They design the system, so the gap never forms.

About the author

Elizabeth Walsh, PMP, ACRP-CP, is a clinical development executive specializing in execution strategy and delivery across complex development programs. With more than 25 years of experience spanning sponsor organizations, CROs, and research environments, she has led global Phase I–IV programs from early development through regulatory submission and commercialization.

Her work focuses on integrating clinical execution into development strategy, ensuring operational assumptions are tested early and sponsor oversight remains active across outsourced models. She has built and led Clinical Operations organizations, supported IND, NDA, and BLA submissions, and guided programs across oncology, rare disease, neurology, immunology, and infectious disease.

She is the founder of Walsh Clinical Advisory, where she advises biotech sponsors on clinical execution and oversight. She is the co-author of The Clinical Execution Blueprint: Aligning Strategy, Oversight, and Delivery in Clinical Development, published in 2026.